Medline MDLN
- Market cap
- $43.8B
- PE
- n/m
- one or more of the four quarters through 2026-06-27 missing
- Forward PE
- 22.7×
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-27 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-27 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-27 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| $6.6B | $6.9B | $7.4B | $7.7B | |
| Cost of revenue | $4.8B | $5B | $5.5B | $5.5B |
| Gross profit | $1.8B | $1.9B | $1.8B | $2.2B |
| SG&A | $1.1B | $1.1B | $1.2B | $1.3B |
| $571M | $642M | $422M | $395M | |
| Interest expense | $244M | $253M | $165M | $168M |
| Pre-tax income | $338M | $359M | $291M | $235M |
| $16M | $26M | $52M | $96M | |
| Net income | n/a | n/a | $132M | $59M |
| n/a | n/a | $0.16 | $0.07 | |
| n/a | n/a | 825M | 861M |
Net income: Q1 FY26 and Q2 FY26: not printed by the filing, worked out from its own lines.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $7.7B | $7.7B to $7.7B | $0.34 | $0.32 to $0.35 | 15 |
| Q4 FY26 | $8.5B | $8.4B to $8.5B | $0.40 | $0.37 to $0.43 | 14 |
| Q1 FY27 | $7.9B | $7.8B to $7.9B | $0.34 | $0.34 to $0.35 | 6 |
| Q2 FY27 | $8.3B | $8.2B to $8.4B | $0.38 | $0.38 to $0.39 | 11 |
| Q3 FY27 | $8.3B | $8.2B to $8.4B | $0.40 | $0.40 to $0.41 | 6 |
| Q4 FY27 | $9.2B | $9.1B to $9.3B | $0.46 | $0.46 to $0.47 | 9 |
| Q1 FY28 | $8.4B | $8.4B to $8.5B | $0.37 | $0.36 to $0.37 | 10 |
| Q2 FY28 | $8.9B | $8.8B to $9B | $0.42 | $0.42 to $0.43 | 7 |
Peers
Companies in Medical - Instruments & Supplies nearest Medline's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MDLNMedline | $43.8B | n/m | n/a | 22.7× | n/m | n/m | n/m |
| BDXBecton, Dickinson and | $54B | 59.9× | 37.5× | 15.0× | 2.6× | +5% | 4.5% |
| RMDResMed | $32.3B | 21.4× | 37.2× | 18.4× | 5.7× | +10% | 26.9% |
| WSTWest Pharmaceutical Services | $28.9B | 52.5× | 45.9× | 44.2× | 8.7× | +12% | 17.0% |
| SOLVSolventum | $14.4B | 10.4× | 10.6× | n/m | 1.7× | −1% | 17.3% |
| ISRGIntuitive Surgical | $154.6B | 52.9× | 69.3× | 36.2× | 13.4× | +20% | 25.5% |
| PENPenumbra | $12.7B | 79.0× | 194× | n/m | 8.4× | +18% | 10.7% |
| COOCooper Companies | $11.7B | 20.9× | 40.2× | n/m | 2.8× | +5% | 13.5% |
| ALGNAlign Technology | $10.9B | 26.8× | 43.3× | n/m | 2.6× | +4% | 10.0% |
| GMEDGlobus Medical | $10.7B | 20.3× | 37.4× | n/m | 3.4× | +20% | 17.0% |
| PODDInsulet | $10.7B | 28.7× | 62.7× | n/m | 3.5× | +29% | 12.3% |
| Peer median | $13.5B | 27.8× | 41.7× | 27.3× | 3.4× | +11% | 15.2% |
Investors who own it
Investors we follow who held Medline at the end of Jun 30, 2026, from their 13F filings.
- John ArmitageEgerton Capital6.3% of portfolioadded
- Stephen MandelLone Pine Capital5.1% of portfolioadded
- Henry EllenbogenDurable Capital Partners1.0% of portfoliotrimmed
- Andreas HalvorsenViking Global Investors0.5% of portfoliotrimmed
- Baillie GiffordBaillie Gifford0.4% of portfolioadded
More on Medline
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .